1/14
Why can't you use direct oral anticoagulants (DOACs) in patients with mechanical valves (MVs)?
DOACs have been one of the most important advances in my career. And yet, the presence of a MV is one of the few contraindications.
The reason highlights the unique nature of thrombus formation in those with a MV and provides insights into the evolution of human hemostasis.
🧬🔬Renal biopsy says amyloidosis… what next?
This brilliant IHC-based algorithm 🔁 guides you through AL, AA, & rare amyloid types—don’t miss that dual diagnosis!
🔗 https://t.co/PiJMb1tIyb 🆕
Dr @VinitaSGPGIMS et. al
#RenalPath#Amyloidosis#Nephrology#MedTwitter
Simple concept of GN. It’s all about location!
1. Subendothelial deposits/injury by Ig, immune-complexes, complement, other mechanism leads to influx of leukocytes= inflammation=GN
2. Subepithelial deposits/injury= protected by GBM & endothelial cells=no inflammation=No GN. 1/3
Ifosfamide
Can cause encephalopathy especially in patients with hypoalbuminemia. IV albumin prophylaxis. IV methylene blue treatment.
Ifos can cause Type II RTA with NAG acidosis, hypokalemia, hypophosphatemia & Fanconi type proteinuria and glucosuria. MESNA cannot prevent this.
All you need to know about the latest JAK inhibitor to be approved for myelofibrosis in this concise review in @BloodJournal by @Bose_Prithviraj of @MDAndersonNews#Leukemia
https://t.co/bPGTTunNJD
#MPNsm
Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma.
#AJH@MayoCancerCare
10 Tables; Algorithms
Includes current data including trials published this month! #ASCO24
https://t.co/B9nLdpfbLK
#EHA2024#EHA24#MPN#mpnsm
Skoda: clonal evolution of MPN, pre-CHIP—> CHIP—>MPN
1) concurrent mutation e.g. DNMT3A confer resistance to therapy
2) pegIFN most efficient way to decrease mutation allelic burden in MPN
3) pegIFN in combination with AZA may overcome concurrent resistant mutation in MPN